Similarly, another aptamer, aptNCL, conjugated with siRNA targeting SLUG (aptNCL‐SLUG) and neuropilin 1 (aptNCL‐NRP1), has been effective in suppressing transcription and downstream signalling pathways, thereby restraining tumour growth, metastasis and angiogenesis in a lung cancer mouse model while preserving healthy cells.83 Here, NRP1 is linked to lung carcinoma.